{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:59Z","timestamp":1794048899644,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhep.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:58:19Z","timestamp":1778889499000},"page":"504-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-0480","authenticated-orcid":false,"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-1764","authenticated-orcid":false,"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5816","authenticated-orcid":false,"given":"Ulus Salih","family":"Akarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viacheslav","family":"Morozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdal","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-2572","authenticated-orcid":false,"given":"Thomas N.","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonko","family":"Pehlivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-400X","authenticated-orcid":false,"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.007_bib4","first-page":"33","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.007_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/gutjnl-2024-332597","article-title":"Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies","volume":"74","author":"Lampertico","year":"2025","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/apt.17878","article-title":"Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection","volume":"59","author":"Sandmann","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cgh.2024.08.008","article-title":"High diagnostic value of transient elastography for advanced fibrosis and cirrhosis in patients with chronic hepatitis delta","volume":"23","author":"Roulot","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jvh.13439","article-title":"A transient early HBV-DNA increase during PEG-IFN\u03b1 therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction","volume":"28","author":"Anastasiou","year":"2021","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1128\/JVI.02155-07","article-title":"Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus","volume":"82","author":"Shih","year":"2008","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int"},{"issue":"40","key":"10.1016\/j.jhep.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"14589","DOI":"10.3748\/wjg.v20.i40.14589","article-title":"Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus","volume":"20","author":"Huang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.jhep.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2893.2012.01597.x","article-title":"Large hepatitis delta antigen activates STAT-3 and NF-\u03baB via oxidative stress","volume":"19","author":"Williams","year":"2012","journal-title":"J Viral Hepat"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/antiox12040974","article-title":"Hepatitis delta virus antigens trigger oxidative stress, activate antioxidant Nrf2\/ARE pathway, and induce unfolded protein response","volume":"12","author":"Smirnova","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.007_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011749","article-title":"Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice","volume":"20","author":"Camps","year":"2024","journal-title":"Plos Pathog"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa2508827","article-title":"A phase 2 trial of tobevibart plus elebsiran in hepatitis D","volume":"394","author":"Asselah","year":"2026","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.007_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2025.10.029","article-title":"Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program","volume":"84","author":"Stern","year":"2026","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826002825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826002825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:33:13Z","timestamp":1787427193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826002825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0168827826002825"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.007","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Johnson & Johnson Innovative Medicine. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}